To evaluate the incidence and variability of traditional coronary artery disease (CAD) risk factors in a cohort of lupus patients and to investigate if prednisone use predicts an increase in the number of risk factors.
Methods
A total of 151 women, 37.8 ± 11.1 (mean ± SD) years old at baseline, were reevaluated after a median period of 39 (interquartile range 36.5–42.0) months. The cumulative incidence of traditional risk factors, the incidence rate (with 95% confidence interval) of hypertension, diabetes, dyslipidemia and hypertriglyceridemia, and the frequency of the risk factors’ disappearance were calculated. Metabolic syndrome (MetS) and Framingham risk score (FRS) were computed. Logistic regression was used to investigate if maximum or cumulative prednisone dose used during follow-up predicted an increase in the cardiometabolic risk factors’ number.
Results
The cumulative incidence of risk factors varied from 39.1% (abdominal obesity) to zero (smoking), and the incidence rate varied from 133.2 (87.8–178.6) per 1000 person-years (dyslipidemia) to 10.4 (1.3–19.5) per 1000 person-years (diabetes). The cumulative incidence for MetS was 18.8%, and 11.7% of 143 patients with low FRS at baseline (T1) were classified in the high-risk category at the end of the study (T2). Dyslipidemia was the most variable risk factor, with 43.5% disappearance at T2. The maximum prednisone dose used during follow-up was borderline (p = 0.050) for prediction of an increase in the number of cardiometabolic risk factors in an adjusted model for antimalarial use, modified Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and age.
Conclusion
The authors described high incidence and variability of CAD risk factors in female lupus patients, with higher prednisone dose being borderline for an increase in the number of cardiometabolic risk factors.
NikpourMGladmanDDUrowitzMB. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?Lupus2013; 22: 1243–1250.
2.
RomanMJShankerBADavisAet al.Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2399–2406.
3.
AsanumaYOeserAShintaniAKet al.Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med2003; 349: 2407–2415.
4.
NikpourMGladmanDDIbanezDHarveyPJUrowitzMB. Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. Arthritis Res Ther2010; 12: R125–R125.
5.
WilhelmAJMajorAS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol2012; 7: 527–539.
6.
TellesRWLannaCCFerreiraGASouzaAJNavarroTPRibeiroAL. Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting. Lupus2008; 17: 105–113.
7.
NikpourMUrowitzMBIbanezDHarveyPJGladmanDD. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Res Ther2011; 13: R156–R156.
8.
KarpIAbrahamowiczMFortinPRet al.Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?Arthritis Rheum2008; 59: 169–175.
9.
PetriMLakattaCMagderLGoldmanD. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med1994; 96: 254–259.
10.
DoriaAShoenfeldYWuRet al.Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis2003; 62: 1071–1077.
11.
SazliyanaSMohd ShahrirMSKongCTTanHJHamidonBBAzmiMT. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus2011; 20: 1260–1266.
12.
BruceIN. “Not only…but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford)2005; 44: 1492–1502.
13.
PetriMSpenceDBoneLRHochbergMC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore)1992; 71: 291–302.
TellesRWLannaCCDFerreiraGACarvalhoMAPRibeiroAL. Frequência de doença cardiovascular aterosclerótica e de seus fatores de risco em pacientes com lúpus eritematoso sistêmico. Rev Bras Reumatol2007; 47: 165–173.
16.
TellesRWLannaCCDFerreiraGARibeiroAL. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus2010; 19: 803–809.
17.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum1997; 40: 1725–1725.
18.
TamEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
19.
WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWB. Prediction of coronary heart disease using risk factor categories. Circulation1998; 97: 1837–1847.
20.
TellesRWLannaCCDSousaAJet al.Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol2013; 32: 1293–1300.
21.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA2001; 285: 2486–2497.
22.
GrundySMCleemanJIDanielsSRet al.Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation2005; 112: 2735–2752.
23.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
24.
LeveyASEckardtKUTsukamotoYet al.Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int2005; 67: 2089–2100.
UribeAGViláLMMcGwinGJrSanchezMLReveilleJDAlarcónGS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol2004; 31: 1934–1940.
27.
GladmanDGinzlerEGoldsmithCet al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
28.
Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation, and Updating. USA: Springer, 2009, pp.174–189.
29.
Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation, and Updating. USA: Springer, 2009, pp.191–211.
30.
PereiraMLunetNPauloCSeveroMAzevedoABarrosH. Incidence of hypertension in a prospective cohort study of adults from Porto, Portugal. BMC Cardiovasc Disord2012; 12: 114–121.
31.
Jimenez-CoronaALopez-RidauraRSternMPGonzalez-VillalpandoC. Risk of progression to hypertension in a low-income Mexican population with prehypertension and normal blood pressure. Am J Hypertens2007; 20: 929–936.
32.
Longo-MbenzaBOn’kinJBKLOkweANKabanguNKFueleSM. Metabolic syndrome, aging, physical inactivity, and incidence of type 2 diabetes in general African population. Diab Vasc Dis Res2010; 7: 28–39.
33.
AsgharSKhanAKAAliSMKet al.Incidence of diabetes in Asian-Indian subjects: a five year follow-up study from Bangladesh. Prim Care Diabetes2011; 5: 117–124.
34.
JosephJSvartbergJNjølstadISchirmerH. Incidence of and risk factors for type-2 diabetes in a general population: the Tromsø Study. Scand J of Public Health2010; 38: 768–775.
35.
HwangJHKamSShinJet al.Incidence of metabolic syndrome and relative importance of five components as a predictor of metabolic syndrome: 5-year follow-up study in Korea. J Korean Med Sci2013; 28: 1768–1773.
36.
MoreiraLBFuchsSCWieheMGusMMoraesRSFuchsFD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens2008; 22: 48–50.
37.
ManziSMeilahnENRairieJEet al.Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol1997; 145: 408–415.
38.
PetriMPerez-GutthannSSpenceDHochbergM. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med1992; 93: 513–519.
39.
BruceINUrowitzMBGladmanDDHallettDC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol1999; 26: 2137–2143.
40.
BorbaEFBonfáE. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus1997; 6: 533–539.
41.
Scala LC, Magalhães LB, Machado A. Epidemiologia da hipertensão arterial sistêmica. In: Moreira SM, Paola AV; Sociedade Brasileira de Cardiologia. Livro Texto da Sociedade Brasileira de Cardiologia. 2nd ed. São Paulo: Manole, 2015, pp.780–785.
42.
Sociedade Brasileira de Cardiologia. Departamento de Hipertensão Arterial. VI Diretrizes brasileiras de hipertensão. Rev Bras Hipertens2010; 17: 4–62.
43.
LeongKHKohETFengPHBoeyML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol1994; 21: 1264–1267.
44.
MacGregorAJDhillonVBBinderAet al.Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis1992; 51: 152–155.
45.
EttingerWHGoldbergAPApplebaum-BowdenDHazzardWR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med1987; 83: 503–508.
46.
BruceINUrowitzMBGladmanDDIbañezDSteinerG. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum2003; 48: 3159–3167.
47.
TangCGodfreyTStawellRNikpourM. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J2012; 42: 968–978.
48.
TamLSGladmanDDHallettDCRahmanPUrowitzMB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol2000; 27: 2142–2145.
49.
WallaceDJMetzgerALStecherVJTurnbullBAKernPA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med1990; 89: 322–326.
50.
SachetJCBorbaEFBonfáEVinagreCGSilvaVMMaranhãoRC. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus2007; 16: 273–278.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
